
Maravai LifeSciences: Enhancing human life through biomedical innovation and proprietary life science technologies.
Founded with a mission to enhance human life through biomedical innovation, Maravai LifeSciences Holdings focuses on providing essential reagents and technologies for nucleic acid production and biologics safety testing. The company supports biotech, biopharma, and life science companies globally, enabling the development of novel vaccines, therapeutics, and diagnostics. Maravai's portfolio includes market-leading brands that act as catalysts for scientific breakthroughs, ensuring a reliable supply of high-quality products for critical research and development.
Maravai LifeSciences has garnered support from notable investors and industry leaders, contributing to its rapid growth and significant impact on the life sciences sector. The company's proprietary technologies have been instrumental in advancing biomedical research, particularly in the areas of vaccine development and therapeutic innovation. By working closely with customers throughout all phases of discovery and process development, Maravai has established itself as a key player in the global effort to improve human health through science.
Maravai LifeSciences' most recent funding round was for $1B (USD) in September 2021.
As of Sep 10, 2021, Maravai LifeSciences has disclosed funding of $1B (USD).
Wintech Nano (Suzhou) Co

Jubilant Ingrevia

Metropolis Healthcare

Novogene

Symbiotec Pharmalab

Viyash Scientific

Aurisco Pharmaceutical

Daan Gene
Guangzhou Wondfo Biotech

ST Pharm

Headlands Research

Alloy Therapeutics

GBA Group

LifeLabs

Thermo Fisher Scientific
thermofisher.com

Roivant Sciences
roivant.com

Gilead Sciences
gilead.com

Moderna
modernatx.com

Maverix Biomics
maverixbio.com

Qiagen
qiagen.com